Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS: CLINICAL TRIAL NUMBER: NCT 00567554, www.clinicaltrials.gov.
|
Authors | G von Minckwitz, S Loibl, M Untch, H Eidtmann, M Rezai, P A Fasching, H Tesch, H Eggemann, I Schrader, K Kittel, C Hanusch, J Huober, C Solbach, C Jackisch, G Kunz, J U Blohmer, M Hauschild, T Fehm, V Nekljudova, B Gerber, GBG/AGO-B study groups, K Gnauert, B Heinrich, T Prätz, U Groh, H Tanzer, C Villena, A Tulusan, B Liedtke, J-U Blohmer, K Kittel, C Mau, J Potenberg, J Schilling, M Just, E Weiss, U Bückner, M Wolfgarten, R Lorenz, G Doering, S Feidicker, P Krabisch, U Deichert, D Augustin, G Kunz, K Kast, G von Minckwitz, C Nestle-Krämling, M Rezai, C Höß, J Terhaag, P Fasching, P Staib, B Aktas, T Kühn, F Khandan, V Möbus, C Solbach, H Tesch, E Stickeler, G Heinrich, H Wagner, A Abdallah, T Dewitz, G Emons, A Belau, V Rethwisch, T Lantzsch, C Thomssen, U Mattner, A Nugent, V Müller, T Noesselt, F Holms, T Müller, J-U Deuker, I Schrader, D Strumberg, C Uleer, E Solomayer, I Runnebaum, H Link, O Tomé, H-U Ulmer, B Conrad, G Feisel-Schwickardi, H Eidtmann, C Schumacher, T Steinmetz, I Bauerfeind, S Kremers, D Langanke, U Kullmer, A Ober, D Fischer, A Kohls, W Weikel, J Bischoff, K Freese, M Schmidt, W Wiest, M Sütterlin, M Dietrich, M Grießhammer, D-M Burgmann, C Hanusch, B Rack, C Salat, D Sattler, J Tio, E von Abel, B Christensen, U Burkamp, C-H Köhne, W Meinerz, S-T Graßhoff, T Decker, F Overkamp, I Thalmann, A Sallmann, T Beck, T Reimer, G Bartzke, M Deryal, M Weigel, J Huober, P Weder, C-C Steffens, S Lemster, A Stefek, F Ruhland, M Hofmann, J Schuster, W Simon, U Kronawitter, M Clemens, T Fehm, W Janni, K Latos, W Bauer, A Roßmann, L Bauer, D Lampe, V Heyl, G Hoffmann, F Lorenz-Salehi, J Hackmann, R Schlag |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 25
Issue 12
Pg. 2363-2372
(Dec 2014)
ISSN: 1569-8041 [Electronic] England |
PMID | 25223482
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Everolimus
- Receptor, ErbB-2
- Sirolimus
|
Topics |
- Adult
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Bevacizumab
- Breast Neoplasms
(drug therapy, metabolism)
- Chemotherapy, Adjuvant
- Drug Therapy, Combination
- Everolimus
- Female
- Humans
- Middle Aged
- Receptor, ErbB-2
(metabolism)
- Sirolimus
(administration & dosage, analogs & derivatives, therapeutic use)
- Survival Analysis
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|